# OnCo record mekanistic-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/mekanistic-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "mekanistic-therapeutics" ;
  schema:name "MEKanistic Therapeutics"@en ;
  schema:description "MEKanistic Therapeutics is developing MTX-531, a single tablet designed to block two cancer growth signals, EGFR and PI3K, at the same time, to get around the resistance that develops when only one is blocked. Its first human trial in advanced solid tumours started in October 2026."@en ;
  schema:url <https://onco.cc/companies/mekanistic-therapeutics/>, <https://www.mekanistic.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.mekanistic.com/>, <https://www.mekanistic.com/news.html>, <https://clinicaltrials.gov/study/NCT07874880> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/egfr/> .